| Width: | 325 |
| Tradename: | Elpida |
| Synonyms: | VM 1500; elpivirine |
| Atc Prefix: | None |
| Legal Status: | Rx-only in Russia |
| Cas Number: | 868046-19-9 |
| Pubchem: | 11527519 |
| Unii: | ZC4CGO0RUG |
| Drugbank: | 14929 |
| Iupac Name: | N-[4-[[2-[4-Bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetyl]amino]-3-chlorophenyl]sulfonylpropanamide |
| C: | 24 |
| H: | 17 |
| Br: | 1 |
| Cl: | 2 |
| F: | 1 |
| N: | 3 |
| O: | 5 |
| S: | 1 |
| Stdinchi: | 1S/C24H17BrCl2FN3O5S/c1-2-21(32)31-37(34,35)17-4-6-20(19(27)11-17)30-22(33)9-14-3-5-18(25)24(23(14)28)36-16-8-13(12-29)7-15(26)10-16/h3-8,10-11H,2,9H2,1H3,(H,30,33)(H,31,32) |
| Stdinchikey: | ULTDEARCBRNRGR-UHFFFAOYSA-N |
Elsulfavirine (trade name Elpida; also known as VM 1500) is drug used to treat HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI).[1] [2] [3] Elsulfavirine is a prodrug which is metabolized to the active antiviral agent deselsulfavirine (also known as VM 1500A).[4] It was developed by the Russian company Viriom.[5]
In June 2017, elsulfavirine was approved for use in Russia as an oral formulation for the treatment of HIV-1 infections in combination with other antiretroviral drugs.[4] [6] Currently, elsulfavirine is used in antiretroviral therapy regimens in the Russian Federation, which includes the combination elsulfavirine + lamivudine (or emtricitabine) + tenofovir.[7]
Long-acting injectable formulations of eslulfavarinin and deselsulfavarine are under investigation.[8] [9]
In addition, Roche is investigating the use of elsulfavirin for the treatment of COVID-19 and it is currently in Phase II clinical trials for this possible indication.[5]